Imagine a tiny, high-tech 'plasma jet' that acts like a super-powered cleaner for dental implants. It blasts away stubborn bacteria and slime that normal cleaning can't reach, without using harsh chemicals or drugs. This helps the gums heal and keeps the implant firmly in place so patients don't lose their teeth.
Dental implants frequently fail due to bacterial infections (periimplantitis), affecting 60% of implants. Current treatments often rely on chemicals and lack a way to prevent reinfection effectively.
A mass-producible medical device consisting of a base station and applicators that use plasma technology to disinfect implant surfaces.
If you are a clinic owner dealing with the 60% of implants that get infected within a few years — this project developed a one-button plasma device that kills bacteria in-situ to save the implant. It provides a painless alternative to chemical treatments.
If you are a distributor dealing with a lack of effective tools for periimplantitis — this project developed a mass-producible system that meets European Medical Device Regulations. It targets a market of 16 million patients in Europe needing urgent help.
If you are a provider dealing with the systemic costs of oral infections linked to diabetes and heart disease — this project developed a technology to stop periimplantitis. By saving implants, it reduces the need for expensive replacement surgeries.
Based on available project data, specific pricing and cost details are not provided.
Yes, the project successfully developed a system that is technically market-ready and mass-producible, including the base station and applicators.
Based on available project data, specific patent or licensing terms are not listed, though the technology is developed by Freiburger Medizintechnik GmbH.
Yes, it has passed all necessary tests required by the European regulatory framework, including the Medical Device Regulation (MDR).
The project describes the technology as a 'rapid' solution, though specific treatment times in minutes are not provided.
The project is led by a single German SME, Freiburger Medizintechnik GmbH. With a 100% industry ratio and no university or research partners, the consortium is lean and focused entirely on commercialization and market transfer rather than basic research.
Contact Freiburger Medizintechnik GmbH regarding the AmbiJet commercial rollout.
Contact us to explore licensing or distribution partnerships for AmbiJet.
